Although the expression of AIM2 in the primary tumors derived from non-responder and responder patients who received Nivolumab (anti-PD-1 antibody) and Atezolizumab (anti-PD-L1 antibody) treatment did not show a significant difference in ROC Plotter analysis (Fig. 6A), Kaplan–Meier plots under a maximal risk condition revealed that a higher level of AIM2 expression predominantly correlates with a good progression-free survival rate in cancer patients receiving these four ICIs (Fig. 6B). Here, AIM2 is linked to cancer.